Proteomic analysis in lung tissue of smokers and COPD patients

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Rationale: Although cigarette smoking is the most important risk factor for COPD, COPD develops in only a minority of smokers, suggesting a significant genetic role. To solve the underlying pathophysiologic mechanism, it is critical to understand genes and their final product, ie, proteins. We investigated the exclusive proteins from the lung tissues obtained from COPD patients using proteomics. Methods: Nontumorous lung tissue specimens were obtained from patients who underwent surgery for lung cancer. We included 22 subjects: nonsmokers (n = 8), smokers without COPD (healthy smokers, n = 7), and smokers with COPD (n = 7). Proteins were separated from their spots with two-dimensional polyacrylamide gel electrophoresis and examined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). To validate the proteins from the above procedures, Western blotting and immunohistochemistry were conducted. Results: Twelve protein spots from COPD group significantly increased or decreased compared with the other two groups were chosen for MALDI-TOF-MS analysis. Eight proteins were up-regulated in the COPD group as compared with the nonsmokers. Meanwhile, five proteins from the COPD group were up-regulated and five were down-regulated when compared with healthy smokers. Of these, matrix metalloproteinase (MMP)-13 and thioredoxin-like 2 were significantly increased in the COPD patients by Western blot and immunohistochemistry. MMP-13 was mainly expressed in the alveolar macrophages and type II pneumocytes; however, thioredoxin-like 2 was primarily seen in the bronchial epithelium. Conclusions: MMP-13 and thioredoxin-like 2 in lungs increased in patients with COPD. MMP-13 was mainly expressed in the alveolar macrophages and type II pneumocytes. In contrast, thioredoxin-like 2 was primarily seen in the bronchial epithelium.

Original languageEnglish
Pages (from-to)344-352
Number of pages9
JournalChest
Volume135
Issue number2
DOIs
Publication statusPublished - 2009 Feb 1

Fingerprint

Proteomics
Chronic Obstructive Pulmonary Disease
Lung
Matrix Metalloproteinase 13
Thioredoxins
Proteins
Alveolar Epithelial Cells
Alveolar Macrophages
Mass Spectrometry
Lasers
Epithelium
Western Blotting
Immunohistochemistry
Electrophoresis, Gel, Two-Dimensional
Lung Neoplasms
Smoking

Keywords

  • Matrix metalloproteinase 13
  • Proteomics
  • Pulmonary disease, chronic obstructive
  • TXNL2 protein, human

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Proteomic analysis in lung tissue of smokers and COPD patients. / Lee, Eun Joo; In, Kwang Ho; Kim, Je Hyeong; Lee, Sang Yeub; Shin, Chol; Shim, Jae Jeong; Kang, Kyung Ho; Yoo, Se Hwa; Kim, Chul Hwan; Kim, Han Kyeom; Lee, Sang Hoon; Uhm, Chang Sub.

In: Chest, Vol. 135, No. 2, 01.02.2009, p. 344-352.

Research output: Contribution to journalArticle

@article{6e175653f6704195a44b81cece95e3be,
title = "Proteomic analysis in lung tissue of smokers and COPD patients",
abstract = "Rationale: Although cigarette smoking is the most important risk factor for COPD, COPD develops in only a minority of smokers, suggesting a significant genetic role. To solve the underlying pathophysiologic mechanism, it is critical to understand genes and their final product, ie, proteins. We investigated the exclusive proteins from the lung tissues obtained from COPD patients using proteomics. Methods: Nontumorous lung tissue specimens were obtained from patients who underwent surgery for lung cancer. We included 22 subjects: nonsmokers (n = 8), smokers without COPD (healthy smokers, n = 7), and smokers with COPD (n = 7). Proteins were separated from their spots with two-dimensional polyacrylamide gel electrophoresis and examined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). To validate the proteins from the above procedures, Western blotting and immunohistochemistry were conducted. Results: Twelve protein spots from COPD group significantly increased or decreased compared with the other two groups were chosen for MALDI-TOF-MS analysis. Eight proteins were up-regulated in the COPD group as compared with the nonsmokers. Meanwhile, five proteins from the COPD group were up-regulated and five were down-regulated when compared with healthy smokers. Of these, matrix metalloproteinase (MMP)-13 and thioredoxin-like 2 were significantly increased in the COPD patients by Western blot and immunohistochemistry. MMP-13 was mainly expressed in the alveolar macrophages and type II pneumocytes; however, thioredoxin-like 2 was primarily seen in the bronchial epithelium. Conclusions: MMP-13 and thioredoxin-like 2 in lungs increased in patients with COPD. MMP-13 was mainly expressed in the alveolar macrophages and type II pneumocytes. In contrast, thioredoxin-like 2 was primarily seen in the bronchial epithelium.",
keywords = "Matrix metalloproteinase 13, Proteomics, Pulmonary disease, chronic obstructive, TXNL2 protein, human",
author = "Lee, {Eun Joo} and In, {Kwang Ho} and Kim, {Je Hyeong} and Lee, {Sang Yeub} and Chol Shin and Shim, {Jae Jeong} and Kang, {Kyung Ho} and Yoo, {Se Hwa} and Kim, {Chul Hwan} and Kim, {Han Kyeom} and Lee, {Sang Hoon} and Uhm, {Chang Sub}",
year = "2009",
month = "2",
day = "1",
doi = "10.1378/chest.08-1583",
language = "English",
volume = "135",
pages = "344--352",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "2",

}

TY - JOUR

T1 - Proteomic analysis in lung tissue of smokers and COPD patients

AU - Lee, Eun Joo

AU - In, Kwang Ho

AU - Kim, Je Hyeong

AU - Lee, Sang Yeub

AU - Shin, Chol

AU - Shim, Jae Jeong

AU - Kang, Kyung Ho

AU - Yoo, Se Hwa

AU - Kim, Chul Hwan

AU - Kim, Han Kyeom

AU - Lee, Sang Hoon

AU - Uhm, Chang Sub

PY - 2009/2/1

Y1 - 2009/2/1

N2 - Rationale: Although cigarette smoking is the most important risk factor for COPD, COPD develops in only a minority of smokers, suggesting a significant genetic role. To solve the underlying pathophysiologic mechanism, it is critical to understand genes and their final product, ie, proteins. We investigated the exclusive proteins from the lung tissues obtained from COPD patients using proteomics. Methods: Nontumorous lung tissue specimens were obtained from patients who underwent surgery for lung cancer. We included 22 subjects: nonsmokers (n = 8), smokers without COPD (healthy smokers, n = 7), and smokers with COPD (n = 7). Proteins were separated from their spots with two-dimensional polyacrylamide gel electrophoresis and examined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). To validate the proteins from the above procedures, Western blotting and immunohistochemistry were conducted. Results: Twelve protein spots from COPD group significantly increased or decreased compared with the other two groups were chosen for MALDI-TOF-MS analysis. Eight proteins were up-regulated in the COPD group as compared with the nonsmokers. Meanwhile, five proteins from the COPD group were up-regulated and five were down-regulated when compared with healthy smokers. Of these, matrix metalloproteinase (MMP)-13 and thioredoxin-like 2 were significantly increased in the COPD patients by Western blot and immunohistochemistry. MMP-13 was mainly expressed in the alveolar macrophages and type II pneumocytes; however, thioredoxin-like 2 was primarily seen in the bronchial epithelium. Conclusions: MMP-13 and thioredoxin-like 2 in lungs increased in patients with COPD. MMP-13 was mainly expressed in the alveolar macrophages and type II pneumocytes. In contrast, thioredoxin-like 2 was primarily seen in the bronchial epithelium.

AB - Rationale: Although cigarette smoking is the most important risk factor for COPD, COPD develops in only a minority of smokers, suggesting a significant genetic role. To solve the underlying pathophysiologic mechanism, it is critical to understand genes and their final product, ie, proteins. We investigated the exclusive proteins from the lung tissues obtained from COPD patients using proteomics. Methods: Nontumorous lung tissue specimens were obtained from patients who underwent surgery for lung cancer. We included 22 subjects: nonsmokers (n = 8), smokers without COPD (healthy smokers, n = 7), and smokers with COPD (n = 7). Proteins were separated from their spots with two-dimensional polyacrylamide gel electrophoresis and examined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). To validate the proteins from the above procedures, Western blotting and immunohistochemistry were conducted. Results: Twelve protein spots from COPD group significantly increased or decreased compared with the other two groups were chosen for MALDI-TOF-MS analysis. Eight proteins were up-regulated in the COPD group as compared with the nonsmokers. Meanwhile, five proteins from the COPD group were up-regulated and five were down-regulated when compared with healthy smokers. Of these, matrix metalloproteinase (MMP)-13 and thioredoxin-like 2 were significantly increased in the COPD patients by Western blot and immunohistochemistry. MMP-13 was mainly expressed in the alveolar macrophages and type II pneumocytes; however, thioredoxin-like 2 was primarily seen in the bronchial epithelium. Conclusions: MMP-13 and thioredoxin-like 2 in lungs increased in patients with COPD. MMP-13 was mainly expressed in the alveolar macrophages and type II pneumocytes. In contrast, thioredoxin-like 2 was primarily seen in the bronchial epithelium.

KW - Matrix metalloproteinase 13

KW - Proteomics

KW - Pulmonary disease, chronic obstructive

KW - TXNL2 protein, human

UR - http://www.scopus.com/inward/record.url?scp=60249084174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60249084174&partnerID=8YFLogxK

U2 - 10.1378/chest.08-1583

DO - 10.1378/chest.08-1583

M3 - Article

C2 - 18753468

AN - SCOPUS:60249084174

VL - 135

SP - 344

EP - 352

JO - Chest

JF - Chest

SN - 0012-3692

IS - 2

ER -